These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28682894)

  • 1. The cost-effectiveness of deep brain stimulation for patients with treatment-resistant obsessive-compulsive disorder.
    Moon W; Kim SN; Park S; Paek SH; Kwon JS
    Medicine (Baltimore); 2017 Jul; 96(27):e7397. PubMed ID: 28682894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of deep brain stimulation versus treatment as usual for obsessive-compulsive disorder.
    Ooms P; Blankers M; Figee M; Bergfeld IO; van den Munckhof P; Schuurman PR; Denys D
    Brain Stimul; 2017; 10(4):836-842. PubMed ID: 28457837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Deep Brain Stimulation in Treatment-Resistant Obsessive-Compulsive Disorder: Outcome and Quality of Life at Four to Eight Years Follow-Up.
    Winter L; Saryyeva A; Schwabe K; Heissler HE; Runge J; Alam M; Heitland I; Kahl KG; Krauss JK
    Neuromodulation; 2021 Feb; 24(2):324-330. PubMed ID: 32667114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of radiosurgical capsulotomy versus treatment as usual for treatment-resistant obsessive-compulsive disorder.
    Najera RA; Gregory ST; Shofty B; Anand A; Gadot R; Youngerman BE; Storch EA; Goodman WK; Sheth SA
    J Neurosurg; 2023 Feb; 138(2):347-357. PubMed ID: 35907186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep Brain Stimulation for Parkinson's Disease with Early Motor Complications: A UK Cost-Effectiveness Analysis.
    Fundament T; Eldridge PR; Green AL; Whone AL; Taylor RS; Williams AC; Schuepbach WM
    PLoS One; 2016; 11(7):e0159340. PubMed ID: 27441637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-Refractory Obsessive-Compulsive Disorder in Adults: A Cost-Effectiveness Analysis of Treatment Strategies.
    Gregory ST; Kay B; Smith J; Hall K; De Nadai AS; Quast T; Riemann BC; Storch EA
    J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29419948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep brain stimulation for obsessive-compulsive disorder: A systematic review of randomised controlled trials.
    Vicheva P; Butler M; Shotbolt P
    Neurosci Biobehav Rev; 2020 Feb; 109():129-138. PubMed ID: 31923474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Analysis of Deep Brain Stimulation in Parkinson Disease: Systematic Review of the Literature.
    Becerra JE; Zorro O; Ruiz-Gaviria R; Castañeda-Cardona C; Otálora-Esteban M; Henao S; Navarrete S; Acevedo JC; Rosselli D
    World Neurosurg; 2016 Sep; 93():44-9. PubMed ID: 27216925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep brain stimulation and treatment-resistant obsessive-compulsive disorder: A systematic review.
    Vázquez-Bourgon J; Martino J; Sierra Peña M; Infante Ceberio J; Martínez Martínez MÁ; Ocón R; Menchón JM; Crespo Facorro B; Vázquez-Barquero A
    Rev Psiquiatr Salud Ment (Engl Ed); 2019; 12(1):37-51. PubMed ID: 28676437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Deep Brain Stimulation for Advanced Parkinson's Disease in the United States.
    Pietzsch JB; Garner AM; Marks WJ
    Neuromodulation; 2016 Oct; 19(7):689-697. PubMed ID: 27491661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Deep Brain Stimulation for Parkinson Disease in Taiwan.
    Fann JC; Chang KC; Yen AM; Chen SL; Chiu SY; Chen HH; Liou HH
    World Neurosurg; 2020 Jun; 138():e459-e468. PubMed ID: 32147563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness and threshold analysis of deep brain stimulation vs. treatment-as-usual for treatment-resistant depression.
    Kabotyanski KE; Najera RA; Banks GP; Sharma H; Provenza NR; Hayden BY; Mathew SJ; Sheth SA
    Transl Psychiatry; 2024 Jun; 14(1):243. PubMed ID: 38849334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of deep-brain stimulation for Tourette's syndrome: an initial exploration.
    Dang TTH; Rowell D; Liddle J; Coyne T; Silburn P; Connelly LB
    J Neurol; 2019 Dec; 266(12):2997-3008. PubMed ID: 31485722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-Nine Year Follow-Up of Deep Brain Stimulation for Obsessive-Compulsive Disorder.
    Fayad SM; Guzick AG; Reid AM; Mason DM; Bertone A; Foote KD; Okun MS; Goodman WK; Ward HE
    PLoS One; 2016; 11(12):e0167875. PubMed ID: 27930748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurosurgical Approaches for Treatment-Resistant Obsessive-Compulsive Disorder.
    Shofty B; Gadot R; Provenza N; Storch EA; Goodman WK; Sheth SA
    Psychiatr Clin North Am; 2023 Mar; 46(1):121-132. PubMed ID: 36740348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of deep brain stimulation in combination with best medical therapy, versus best medical therapy alone, in advanced Parkinson's disease.
    Eggington S; Valldeoriola F; Chaudhuri KR; Ashkan K; Annoni E; Deuschl G
    J Neurol; 2014 Jan; 261(1):106-16. PubMed ID: 24158271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of neurostimulation in Parkinson's disease with early motor complications.
    Dams J; Balzer-Geldsetzer M; Siebert U; Deuschl G; Schuepbach WM; Krack P; Timmermann L; Schnitzler A; Reese JP; Dodel R;
    Mov Disord; 2016 Aug; 31(8):1183-91. PubMed ID: 27506638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deep brain stimulation versus anterior capsulotomy for obsessive-compulsive disorder: a review of the literature.
    Pepper J; Hariz M; Zrinzo L
    J Neurosurg; 2015 May; 122(5):1028-37. PubMed ID: 25635480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
    Walter E; Odin P
    J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.